The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC.
 
Hira Rizvi
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Megan Tenet
No Relationships to Disclose
 
Darragh Halpenny
No Relationships to Disclose
 
Niamh Long
No Relationships to Disclose
 
Jennifer L. Sauter
Stock and Other Ownership Interests - Merck; Thermo Fisher Scientific
 
Francisco Sanchez-Vega
No Relationships to Disclose
 
Walid K Chatila
No Relationships to Disclose
 
Nikolaus Schultz
No Relationships to Disclose
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - NCCN/AstraZeneca; NCCN/Boehringer Ingelheim
Research Funding - Loxo (Inst)
 
Kathryn Cecilia Arbour
No Relationships to Disclose
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb